Man Group plc Invests $80.46 Million in Kenvue Inc. $KVUE

Man Group plc purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,210,418 shares of the company’s stock, valued at approximately $80,461,000.

Several other institutional investors have also recently bought and sold shares of KVUE. Callan Family Office LLC bought a new position in shares of Kenvue in the 2nd quarter valued at about $835,000. Calamos Advisors LLC raised its stake in shares of Kenvue by 24.1% during the first quarter. Calamos Advisors LLC now owns 3,351,000 shares of the company’s stock worth $57,771,000 after buying an additional 651,000 shares during the last quarter. State of Wyoming lifted its holdings in Kenvue by 233.5% in the fourth quarter. State of Wyoming now owns 97,992 shares of the company’s stock valued at $1,690,000 after buying an additional 68,609 shares during the period. Nomura Asset Management Co. Ltd. lifted its holdings in Kenvue by 21.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 3,491,548 shares of the company’s stock valued at $60,229,000 after buying an additional 618,720 shares during the period. Finally, Nuance Investments LLC bought a new position in Kenvue in the second quarter valued at approximately $27,681,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.4%

Shares of NYSE KVUE opened at $19.34 on Wednesday. The stock has a market cap of $37.16 billion, a P/E ratio of 22.24, a P/E/G ratio of 1.39 and a beta of 0.47. The firm has a 50 day moving average price of $19.10 and a 200 day moving average price of $18.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.40.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same quarter last year, the business posted $0.29 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

Analyst Ratings Changes

A number of analysts have commented on the stock. UBS Group lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Barclays increased their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.